Cargando…
Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currentl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal of Therapeutics
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812412/ https://www.ncbi.nlm.nih.gov/pubmed/36048531 http://dx.doi.org/10.1097/MJT.0000000000001548 |
_version_ | 1784863720176877568 |
---|---|
author | Bryant, Andrew Grayling, Michael Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj |
author_facet | Bryant, Andrew Grayling, Michael Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj |
author_sort | Bryant, Andrew |
collection | PubMed |
description | Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currently available evidence to date in this area, opponents remain skeptical. AREAS OF UNCERTAINTY: We aimed to conduct sensitivity analyses to adjust for potential publication bias, to confirm or refute existing conclusions and recommendations, leveraging elicitation to incorporate expert opinion. We recommend our approach as an exemplar that should be adopted in other areas of research. DATA SOURCES: We conducted random-effects network meta-analyses in frequentist and Bayesian (using Markov Chain Montel Carlo simulation) frameworks comparing OS across residual disease thresholds in women with advanced epithelial ovarian cancer after primary cytoreductive surgery. Elicitation methods among experts in gynecology were used to derive priors for an extension to a previously reported Copas selection model and a novel approach using effect estimates calculated from the elicitation exercise, to attempt to adjust for publication bias and increase confidence in the certainty of the evidence. THERAPEUTIC ADVANCES: Analyses using data from 25 studies (n = 20,927 women) all showed the prognostic importance of complete cytoreduction (0 cm) in both frameworks. Experts accepted publication bias was likely, but after adjustment for their opinions, published results overpowered the informative priors incorporated into the Bayesian sensitivity analyses. Effect estimates were attenuated but conclusions were robust in all analyses. CONCLUSIONS: There remains a strong association between the achievement of complete cytoreduction and improved OS even after adjustment for publication bias using strong informative priors formed from an expert elicitation exercise. The concepts of the elicitation survey should be strongly considered for utilization in other meta-analyses. |
format | Online Article Text |
id | pubmed-9812412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Journal of Therapeutics |
record_format | MEDLINE/PubMed |
spelling | pubmed-98124122023-01-12 Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias Bryant, Andrew Grayling, Michael Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Am J Ther Therapeutic Advance Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currently available evidence to date in this area, opponents remain skeptical. AREAS OF UNCERTAINTY: We aimed to conduct sensitivity analyses to adjust for potential publication bias, to confirm or refute existing conclusions and recommendations, leveraging elicitation to incorporate expert opinion. We recommend our approach as an exemplar that should be adopted in other areas of research. DATA SOURCES: We conducted random-effects network meta-analyses in frequentist and Bayesian (using Markov Chain Montel Carlo simulation) frameworks comparing OS across residual disease thresholds in women with advanced epithelial ovarian cancer after primary cytoreductive surgery. Elicitation methods among experts in gynecology were used to derive priors for an extension to a previously reported Copas selection model and a novel approach using effect estimates calculated from the elicitation exercise, to attempt to adjust for publication bias and increase confidence in the certainty of the evidence. THERAPEUTIC ADVANCES: Analyses using data from 25 studies (n = 20,927 women) all showed the prognostic importance of complete cytoreduction (0 cm) in both frameworks. Experts accepted publication bias was likely, but after adjustment for their opinions, published results overpowered the informative priors incorporated into the Bayesian sensitivity analyses. Effect estimates were attenuated but conclusions were robust in all analyses. CONCLUSIONS: There remains a strong association between the achievement of complete cytoreduction and improved OS even after adjustment for publication bias using strong informative priors formed from an expert elicitation exercise. The concepts of the elicitation survey should be strongly considered for utilization in other meta-analyses. American Journal of Therapeutics 2022-11-01 /pmc/articles/PMC9812412/ /pubmed/36048531 http://dx.doi.org/10.1097/MJT.0000000000001548 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Therapeutic Advance Bryant, Andrew Grayling, Michael Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title | Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title_full | Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title_fullStr | Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title_full_unstemmed | Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title_short | Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias |
title_sort | residual disease after primary surgical treatment for advanced epithelial ovarian cancer, part 2: network meta-analysis incorporating expert elicitation to adjust for publication bias |
topic | Therapeutic Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812412/ https://www.ncbi.nlm.nih.gov/pubmed/36048531 http://dx.doi.org/10.1097/MJT.0000000000001548 |
work_keys_str_mv | AT bryantandrew residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT graylingmichael residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT elattarahmed residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT gajjarketankumar residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT craigdawn residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT valeluke residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias AT naikraj residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias |